Physician profile
Rinu Mathew
NPI 1649785049
$4,151.72
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,501 · 2022: $1,651.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,366.65 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $429.86 | 2021-2022 | |
| Glaxosmithkline, LLC. | $421.58 | 2021-2022 | |
| Amgen INC. | $337.65 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $283.04 | 2021-2022 | |
| Insmed, INC. | $151.96 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $140.56 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $128.83 | 2021-2022 | |
| Inspire Medical Systems, INC. | $120.67 | 2021 | |
| Gilead Sciences, INC. | $97.03 | 2021-2022 | |
| Genentech USA, INC. | $96.45 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $85.96 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $75.00 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.88 | 2022 | |
| Genzyme Corporation | $46.59 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $45.72 | 2022 | |
| Harmony Biosciences LLC | $37.90 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $37.33 | 2021 | |
| Mylan Specialty L.P. | $35.03 | 2022 | |
| Sanofi-Aventis U.S. LLC | $34.92 | 2021 | |
| Pfizer INC. | $22.92 | 2022 | |
| Baxter Healthcare | $21.68 | 2022 | |
| Inogen, INC. | $19.62 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.42 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.41 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.84 | 2021 | |
| Collegium Pharmaceutical, INC. | $12.22 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rinu Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.